Abstract
Sporadic inclusion body myositis (sIBM) is a chronic and progressive inflammatory myopathy that is the commonest among population over 50s. Recently, autoantibodies against cytosolic 5′-nucleotidase 1A (cN1A) have been identified in plasma and serum samples from patients with sIBM. So far, various methods have been established to detect the anti-cN1A autoantibodies, which showed a clinical utility of detection of the autoantibodies in the diagnosis of sIBM. Here we describe a novel cell-based assay for detection of the autoantibodies, which seems equivalent in sensitivity and better in specificity for the diagnosis of sIBM, compared with the previous methods.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP (1995) Inclusion body myositis and myopathies. Ann Neurol 38(5):705–713. https://doi.org/10.1002/ana.410380504
Needham M, Mastaglia FL (2007) Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6(7):620–631. https://doi.org/10.1016/S1474-4422(07)70171-0
Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC (2015) Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve 52(4):527–533. https://doi.org/10.1002/mus.24562
Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, Kong SW, Pinkus JL, Amato AA, Elledge SJ, Greenberg SA (2013) Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 73(3):408–418. https://doi.org/10.1002/ana.23840
Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, Verbeek MM, Badrising UA, Arnardottir S, Gheorghe K, Lundberg IE, Boelens WC, van Engelen BG, Pruijn GJ (2013) Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol 73(3):397–407. https://doi.org/10.1002/ana.23822
Salajegheh M, Lam T, Greenberg SA (2011) Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 6(5):e20266. https://doi.org/10.1371/journal.pone.0020266
Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, Danoff SK, Pak K, Casciola-Rosen LA, Mammen AL (2016) Cytosolic 5'-Nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken) 68(1):66–71. https://doi.org/10.1002/acr.22600
Goyal NA, Cash TM, Alam U, Enam S, Tierney P, Araujo N, Mozaffar FH, Pestronk A, Mozaffar T (2016) Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry 87(4):373–378. https://doi.org/10.1136/jnnp-2014-310008
Greenberg SA (2014) Cytoplasmic 5′-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve 50(4):488–492. https://doi.org/10.1002/mus.24199
Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, Lamb JA, Cooper RG, Roberts M, Badrising UA, De Bleecker JL, Machado PM, Hanna MG, Plestilova L, Vencovsky J, van Engelen BG, Pruijn GJ (2016) Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 75(4):696–701. https://doi.org/10.1136/annrheumdis-2014-206691
Tawara N, Yamashita S, Zhang X, Korogi M, Zhang Z, Doki T, Matsuo Y, Nakane S, Maeda Y, Sugie K, Suzuki N, Aoki M, Ando Y (2017) Pathomechanisms of anti-cytosolic 5′-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol 81(4):512–525. https://doi.org/10.1002/ana.24919
Acknowledgments
This work was supported by a Grant-in-Aid for Scientific Research (24591269) from the Japan Society for the Promotion of Science (JSPS), Japan; and a Grant-in-Aid for Research on Intractable Diseases from the Ministry of Health, Labour, and Welfare of Japan. We thank all members of the Department of Diagnostic Medicine and the Department of Neurology, and of Kumamoto University Hospital, for biochemical and histological analyses.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Yamashita, S., Tawara, N. (2019). Determination of cN1A Autoantibodies by Cell-Based Immunofluorescence Cytochemistry. In: Houen, G. (eds) Autoantibodies. Methods in Molecular Biology, vol 1901. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8949-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8949-2_7
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8948-5
Online ISBN: 978-1-4939-8949-2
eBook Packages: Springer Protocols